Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase 2 study of bevacizumab and irinotecan as second-line therapy in patients with advanced colorectal cancer previously treated with oxaliplatin and bavacizumab

ABSTRACT: Interventions: Bevacizumab+Irinotecan Bevacizumab: 10mg/kg d.i.v. day1 Irinotecan:150mg/m2 d.i.v.day1 to be repeated every 2 weeks Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2622484 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II study of XELIRI and High-dose bevacizumab as second-line therapy in patients with metastatic colorectal cancer

Project description:Interventions: XELIRI plus bevacizumab therapy Bevacizumab 10mg/kg day1 Irinotecan 150mg/m2 day1 Capecitabin 2,000mg/m2/day day1-8 Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2623833 | ecrin-mdr-crc

A Phase II Study of Bi-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy

Project description:Interventions: XELIRI plus bevacizumab therapy Capecitabine: 2000 mg/m2 day1 to 8 CPT11 150mg/m2 day1 Bevacizumab: 10mg/kg day 1 The treatment is repeated every two weeks until disease progression or severe toxicity. Primary outcome(s): progression free survival and safety Study Design: Single arm Non-randomized

| 2624679 | ecrin-mdr-crc

Phase II study of bevacizumab and irinotecan as second-line therapy in patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab

Project description:Interventions: 1) Bevacizumab 10mg/kg is administered by 10-30min. intravenous infusion, followed by irinotecan 150mg/m2 by 90 min infusion (2)Patients should be received this chemotherapy biweekly until disease progression Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2620667 | ecrin-mdr-crc

Phase II study of S-1 plus irinotecan combined with bevacizumab as 2nd-line chemotherapy in patients with unresectable colorectal cancer, who had previously received oxaliplatin-based chemotherapy.

Project description:Interventions: CPT-11 150mg/m2 i.v. (day1) Bev 7.5mg/kg i.v. (day1) S-1 80mg/m2 p.o. (day1-14) to be repeated every 3 weeks Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2621739 | ecrin-mdr-crc

TAS-102, Irinotecan, and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO), A Phase II Clinical Trial. ClinicalTrials.gov NCT04109924

Project description:Background: The efficacy of FOLFIRI plus an antiangiogenesis biologic agent as 2nd line therapy for metastatic colorectal adenocarcinoma is limited. TAS-102 is a novel oral antimetabolite with a distinct mechanism of action from fluoropyrimidines. We evaluated the antitumor efficacy of TAS-102, irinotecan and bevacizumab in patients with pre-treated, advanced colorectal adenocarcinoma in a multicenter, phase II, single-arm study. Methods: Patients with advanced colorectal adenocarcinoma who had progressed after oxaliplatin and fluoropyrimidine and were eligible for treatment with bevacizumab were treated with irinotecan, bevacizumab, and TAS-102 in 28-day cycles. The primary endpoint was progression-free survival (PFS). Results: We enrolled 35 evaluable patients. The study was positive. The median PFS was 7.9 (90% CI 6.2-11.8) months (vs. 6 months in historical control, p=0.018). The median overall survival was 16.5 (90% CI 9.8-17.5) months. Sixty-seven percent of patients experienced grade 3 or higher treatment-related adverse events. The most common toxicities were hematological (neutropenia) and gastrointestinal (diarrhea, nausea, and vomiting). Conclusions: Irinotecan, TAS-102 and bevacizumab is an active 2nd line therapy for patients with metastatic colorectal adenocarcinoma. Neutropenia is common and can affect dose density/intensity mandating use of G-CSF. A randomized study versus standard of care therapy is warranted.

2024-08-26 | GSE275628 | GEO

A randomized phase II study of XELOX plus Bevacizumab versus XELIRI plus Bevacizumab for advanced colorectal cancer with or without mitochondrial transcription factor A (mtTFA) expression.

Project description:Interventions: mtTFA(+):Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression mtTFA(+):Irinotecan 200mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine1,600mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression mtTFA(-):Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression mtTFA(-):Irinotecan 200mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine1,600mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression Primary outcome(s): Response rate with or without mtTFA expression Study Design: Parallel Randomized

| 2620502 | ecrin-mdr-crc

Phase II study of XELIRI and bevacizumab as second-line therapy in patients with metastatic colorectal cancer

Project description:Interventions: XELIRI plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Irinotecan 160mg/m2 day1 Capecitabin 1,600mg/m2/day day1-15 Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2624073 | ecrin-mdr-crc

Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine,oxaliplatin plus bevacizumab for metastatic colorectal cancer

Project description:Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 irinotecan 130mg/m2 day1 Capecitabin 1600mg/m2/day day1-15 Primary outcome(s): ORR;Overall response rate Study Design: Single arm Non-randomized

| 2627045 | ecrin-mdr-crc

Clinical efficacy and biomarker assessment of Capecitabine plus oxaliplatin (XELOX) in combination with Bevacizumab as second-line therapy in patients with advanced or recurrent colorectal cancer after failure to irinotecan. Multi-center phase II Study.

Project description:Interventions: Capecitabine plus oxaliplatin (XELOX) in combination with Bevacizumab. Capecitabine:2000mg/m2/day p.o.(day1-15) Oxaliplatin:130mg/m2 i.v.(day1) Bevacizumab:7.5mg/kg i.v.(day1) to be repeated every 3 weeks Primary outcome(s): 6-month Progression free survival rate Study Design: Single arm Non-randomized

| 2620624 | ecrin-mdr-crc

Phase II study of S-1+CPT-11+Bevacizumab as second-line therapy in metastatic colorectal cancer which has prior therapy of S-1+L-OHP+Bevacizumab

Project description:Interventions: Bevacizumab 7.5mg/kg/tri-week CPT-11 150mg/m2/tri-week S-1 40-60mg/twice/day(day1-15)/tri-week Primary outcome(s): Progression-free survival Study Design: Single arm Non-randomized

| 2630432 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data